# 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer

> **NCT01162785** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 7 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** SCH 721015

## Key facts

- **NCT ID:** NCT01162785
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2016-11-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01162785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01162785, "1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01162785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*